Current treatment status-Undergoing active treatment-Minimal response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Minimal response Posts on Medivizor

Evaluating a new CAR-T cell therapy for patients with relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects.   Some background MM is a type of cancer of the...

Read More

Evaluating ixazomib, cyclophosphamide and dexamethasone treatment for relapsed/refractory multiple myeloma

Posted by on Dec 22, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...

Read More

Evaluating cardiovascular safety of carfilzomib in patients with relapsed or refractory multiple myeloma

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...

Read More